This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in JAMA  Topic Collections  • Psychiatry  • Tobacco  • Randomized Controlled Trial  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: In their clinical trials of varenicline for smoking cessation, Dr Gonzales and colleagues,¹ Dr Jorenby and colleagues,² and Dr Tonstad and colleagues³ used broad exclusion criteria, particularly for psychiatric disorders of major depressive disorder within the past year; history of or a current panic disorder, psychosis, bipolar disorder, or eating disorder; or alcohol or drug abuse or dependency within the past year. In addition, Tonstad et al³ excluded potential participants who were taking antidepressants, antipsychotics, or mood stabilizers or anticonvulsants.

However, it is estimated that 30% of smokers have some form of mental illness.⁴ Moreover, Lasser et al⁵ estimated that persons diagnosed as having a mental disorder within the past month consumed 44% of all cigarettes smoked in the United States. Therefore, the extensive psychiatric exclusion criteria in these trials may make it difficult to apply their results to the general population of smokers. In addition, patients . . . [Full Text of this Article]

Alain Dervaux, MD
a.dervaux@ch-sainte-anne.fr

Mostafa Kanit, MD; Xavier Laqueille, MD
Substance Abuse Treatment Department
Centre Hospitalier Sainte-Anne
Paris, France

RELATED LETTER

Efficacy of Varenicline for Smoking Cessation—Reply
Douglas E. Jorenby, Serena Tonstad, and David Gonzales
JAMA. 2006;296(21):2555-2556.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial
David Gonzales, Stephen I. Rennard, Mitchell Nides, Cheryl Oncken, Salomon Azoulay, Clare B. Billing, Eric J. Watsky, Jason Gong, Kathryn E. Williams, Karen R. Reeves, and for the Varenicline Phase 3 Study Group
JAMA. 2006;296(1):47-55.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Update in Chronic Obstructive Pulmonary Disease 2006
Rabe et al.
Am. J. Respir. Crit. Care Med. 2007;175:1222-1232.
FULL TEXT